https://www.selleckchem.com/pr....oducts/CHR-2797(Tose
0001), and oxygen-dependency (53% vs 80%, P=0.001) and prescription of AZI±HCQ (from 25% to 76%, P0.0001) were also greater over time. Multivariate analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ (hazard ratio [HR]=0.45, 95% confidence interval [CI 0.21-0.97], P=0.04), particularly among an identified category of individuals (lymphocyte ≥1000/mm or CRP ≥100 mg/L). The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors
Like
Comment
Share
